Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study)

20260 citationsJournal Articlegold Open Access

Authors

Kazuko Yamamoto · University of the Ryukyus

Naoki Iwanaga · Nagasaki University Hospital

Asuka Umemura · Sasebo City General Hospital

Toyomitsu Sawai · Nagasaki Medical Center

Makoto Sumiyoshi · Japan Community Healthcare Organization

Kohji Hashiguchi · Japanese Red Cross Society, Japan

Yusuke Mori

Abstract

Japan Registry of Clinical Trials (jRCT; registration number: jRCTs071210011; https://jrct.mhlw.go.jp/latest-detail/jRCTs071210011) on April 13, 2021.

Topics & Keywords

Pneumonia and Respiratory Infections Pharmacological Receptor Mechanisms and Effects Long-Term Effects of COVID-19

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Therapeutic Advances in Infectious Disease

Volume 13, pp. 20499361261431488-20499361261431488

DOI: 10.1177/20499361261431488

Field-Weighted Citation Impact: 0.00